Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Salivary Gland Carcinoma
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Salivary Gland Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab VM Oncology, LLC | Phase 2 | B |
Anti-Her2 Antibody-Drug Conjugate A166 Klus Pharma Inc. | Phase 1/2 | CCC |
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- VM Oncology, LLC | Phase 1/2 | CCC |
Lenalidomide National Cancer Institute (NCI) | Phase 1 | CC |
Sargramostim National Cancer Institute (NCI) | Phase 1 | CC |
View all 13 →
Same molecule, other indications
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →